Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aclaris Therapeutics Inc (ACRS): RA Capital Management Disposes of 1.1 Million Shares

Page 1 of 8

An amended 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics Inc (NASDAQ:ACRS), decreasing its stake in the company to 1.53 million shares, which account for 7.1% of the stock’s float. As per its 13F filing for the end of June, RA Capital Management’s stake consisted of 2.63 million common shares.

Aclaris Therapeutics Inc (NASDAQ:ACRS) is a clinical-stage pharmaceutical company that works on producing various therapeutics for treating dermatological problems. Over the past 12 months, the company’s stock has gained an outstanding 122.81%. In its financial report for the second quarter of 2016, Aclaris Therapeutics disclosed a net loss of $12.87 million and a net loss per share of $0.62, which compares to a net loss of $2.59 million and a net loss per share of $1.52 for the same period of the previous year. Recently, JMP Securities initiated coverage on Aclaris Therapeutics’ stock, placing an ‘Outperform’ rating on it and a price target of $34.

Peter Kolchinsky

As per our hedge fund database, four investors that we track were long Aclaris Therapeutics Inc (NASDAQ:ACRS) at the end of June, same as a quarter earlier. Some of the bullish investors aside from RA Capital Management encompassed Kris Jenner, Gordon Bussard, and Graham Mcphail’s Rock Springs Capital Management, which held a position worth $18.47 million, and Bihua Chen’s Cormorant Asset Management, with a position valued at $16.65 million.

Follow Aclaris Therapeutics Inc.
Trade (ACRS) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 1,530,020 0 1,530,020 1,530,020 7.1%
Peter Kolchinsky 0 1,530,020 0 1,530,020 1,530,020 7.1%
RA Capital Healthcare Fund 0 1,304,714 0 1,304,714 1,304,714 6.1%

Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

Page 1 of 8 – SEC Filing

Washington, D.C. 20549


Under the Securities Exchange Act of

(Amendment No. 2)*

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per

(Title of Class of Securities)


(CUSIP Number)

September 26, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Page 1 of 8

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!